SCHEMBL18512948

SCHEMBL18512948

Cc1cn([C@@H]2O[C@H](CO)[C@H](O)[C@@H]2O)c(=O)nc1N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
MTOR P42345 2/20 0.62
ALDH1A1 P00352 2/20 0.62
TP53 P04637 2/20 0.62
THRB P10828 1/20 0.62
MDM2 Q00987 1/20 0.62
NCOA1 Q15788 1/20 0.62
NCOA3 Q9Y6Q9 1/20 0.62
GMNN O75496 1/20 0.62
NFKB1 P19838 1/20 0.62
DNMT1 P26358 1/20 0.62
THPO P40225 1/20 0.62
HTT P42858 1/20 0.62
RAB9A P51151 1/20 0.62
BLM P54132 1/20 0.62
HBB P68871 1/20 0.62
PMP22 Q01453 1/20 0.62
MAPT P10636 2/20 0.52
CDA P32320 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182161 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL41572 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL2579580 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL14441083 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL6297856 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL5953706 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL14929291 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL5697581 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL5953287 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB
SCHEMBL15630246 1.00 LMNA (0.62) LMNAMTORALDH1A1TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339441-B2 Profiling chemically modified DNA/RNA units for disease and cancer diagnosis THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-24 US disclosed
US-11331331-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto EMORY UNIVERSITY (US) 2022-05-17 US disclosed
US-20220016153-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-20 US disclosed
US-11197882-B2 2021-12-14 US disclosed
US-11147826-B2 2021-10-19 US disclosed
US-20200276219-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-09-03 US disclosed
US-20190255194-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX INC (US) 2019-08-22 US disclosed
US-20170044619-A1 PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331331-B2 N4-hydroxycytidine and derivatives and anti-viral uses related thereto ENTPD1, NME2, NME1 LMNA 2101/4885MTOR 2508/4885ALDH1A1 1480/4885
US-20190255194-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 LMNA 571/4885MTOR 4711/4885ALDH1A1 2324/4885
US-11147826-B2 SNRPE, NME2, NME1 LMNA 2186/4885MTOR 1816/4885ALDH1A1 920/4885
US-20220016153-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO ENTPD1, NME2, NME1 LMNA 2101/4885MTOR 2508/4885ALDH1A1 1480/4885
US-20200276219-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO ENTPD1, NME2, NME1 LMNA 2101/4885MTOR 2508/4885ALDH1A1 1480/4885
US-11197882-B2 SNRPE, NME2, NME1 LMNA 2186/4885MTOR 1816/4885ALDH1A1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.